Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. Our industry leading platforms are based on pluripotent stem cells and allogeneic immunotherapy. Current programs focus on spinal cord injury and cancer. We are traded on the NYSE MKT under the ticker symbol AST.
Asterias is conducting a clinical study to evaluate the safety and activity of AST-OPC1 in patients with complete cervical spinal cord injury. AST-OPC1 consists of cells known as oligodendrocyte progenitor cells (OPCs). The purpose of the study is to evaluate the safety of AST-OPC1 administered once between 14 and 30 days after injury. Researchers will also assess the impact on patient hand and arm function.
Asterias Biotherapeutics to Present at the 4th Annual Gateway Investor Conference
To view the webcast please click here